Avantra Family Wealth Inc. lifted its position in CVS Health Corporation (NYSE:CVS - Free Report) by 41.7% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 15,982 shares of the pharmacy operator's stock after purchasing an additional 4,704 shares during the quarter. CVS Health accounts for 1.0% of Avantra Family Wealth Inc.'s portfolio, making the stock its 23rd largest position. Avantra Family Wealth Inc.'s holdings in CVS Health were worth $1,083,000 at the end of the most recent reporting period.
A number of other large investors have also recently bought and sold shares of the stock. Hopwood Financial Services Inc. acquired a new stake in shares of CVS Health during the fourth quarter worth about $29,000. McIlrath & Eck LLC boosted its stake in CVS Health by 32.6% in the 4th quarter. McIlrath & Eck LLC now owns 707 shares of the pharmacy operator's stock valued at $32,000 after purchasing an additional 174 shares during the period. Providence First Trust Co bought a new stake in CVS Health in the 4th quarter valued at $42,000. Park Square Financial Group LLC bought a new stake in CVS Health in the 4th quarter valued at $43,000. Finally, PARK CIRCLE Co lifted its position in shares of CVS Health by 42.9% during the 4th quarter. PARK CIRCLE Co now owns 1,000 shares of the pharmacy operator's stock valued at $45,000 after acquiring an additional 300 shares during the period. 80.66% of the stock is currently owned by institutional investors.
Insider Transactions at CVS Health
In other CVS Health news, Director Guy P. Sansone acquired 1,570 shares of the firm's stock in a transaction that occurred on Thursday, June 5th. The shares were purchased at an average cost of $63.70 per share, for a total transaction of $100,009.00. Following the completion of the acquisition, the director now owns 12,007 shares of the company's stock, valued at approximately $764,845.90. The trade was a 15.04% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Company insiders own 1.22% of the company's stock.
CVS Health Stock Down 0.2%
Shares of NYSE CVS traded down $0.15 during mid-day trading on Friday, reaching $66.69. 11,828,346 shares of the company's stock traded hands, compared to its average volume of 10,923,499. The company has a debt-to-equity ratio of 0.77, a current ratio of 0.82 and a quick ratio of 0.63. The stock has a market cap of $84.36 billion, a P/E ratio of 15.92, a PEG ratio of 0.95 and a beta of 0.56. CVS Health Corporation has a 1-year low of $43.56 and a 1-year high of $72.51. The business has a 50-day simple moving average of $64.92 and a 200 day simple moving average of $60.42.
CVS Health (NYSE:CVS - Get Free Report) last released its earnings results on Thursday, May 1st. The pharmacy operator reported $2.25 earnings per share for the quarter, beating analysts' consensus estimates of $1.62 by $0.63. The firm had revenue of $94.59 billion for the quarter, compared to analysts' expectations of $93.07 billion. CVS Health had a net margin of 1.39% and a return on equity of 10.59%. The company's quarterly revenue was up 7.0% on a year-over-year basis. During the same period in the previous year, the company earned $1.31 earnings per share. On average, analysts expect that CVS Health Corporation will post 5.89 EPS for the current fiscal year.
Wall Street Analyst Weigh In
A number of analysts have recently weighed in on CVS shares. Wall Street Zen upgraded CVS Health from a "hold" rating to a "buy" rating in a research report on Friday, May 9th. Piper Sandler upped their target price on CVS Health from $72.00 to $74.00 and gave the company an "overweight" rating in a research report on Friday, March 21st. Royal Bank Of Canada upped their target price on CVS Health from $74.00 to $81.00 and gave the company an "outperform" rating in a research report on Monday, May 5th. Barclays set a $79.00 price target on CVS Health and gave the stock an "overweight" rating in a report on Monday, June 2nd. Finally, Robert W. Baird boosted their price target on CVS Health from $51.00 to $71.00 and gave the stock a "neutral" rating in a report on Tuesday, April 15th. Two analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, CVS Health currently has an average rating of "Moderate Buy" and a consensus price target of $74.75.
Get Our Latest Stock Analysis on CVS
About CVS Health
(
Free Report)
CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.
Further Reading
Before you consider CVS Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.
While CVS Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
